Use of sting agonists to treat hepatitis B virus infection
US9642830B2 · kind B2 · utility
5Cited by
0References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 21, 2014 |
| Grant date | May 9, 2017 |
| Priority date | — |
| Expiry date | Oct 21, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention includes methods of treating a subject having hepatitis B viral (HBV) infection. In certain embodiments, the method of the invention comprises stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular STING agonists, thus suppressing HBV replication in hepatocytes. In other embodiments, the method of the invention can be used to treat chronic HBV infections. The invention further provides methods of identifying compounds useful in treating HBV infection in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.